» Articles » PMID: 32361569

Breast Cancer: Biology, Biomarkers, and Treatments

Overview
Date 2020 May 4
PMID 32361569
Citations 284
Authors
Affiliations
Soon will be listed here.
Abstract

During the past recent years, various therapies emerged in the era of breast cancer. Breast cancer is a heterogeneous disease in which genetic and environmental factors are involved. Breast cancer stem cells (BCSCs) are the main player in the aggressiveness of different tumors and also, these cells are the main challenge in cancer treatment. Moreover, the major obstacle to achieve an effective treatment is resistance to therapies. There are various types of treatment for breast cancer (BC) patients. Therefore, in this review, we present the current treatments, novel approaches such as antibody-drug conjugation systems (ADCs), nanoparticles (albumin-, metal-, lipid-, polymer-, micelle-based nanoparticles), and BCSCs-based therapies. Furthermore, prognostic and predictive biomarkers will be discussed also biomarkers that have been applied by some tests such as Oncotype DX, Mamm αPrint, and uPA/PAI-1 are regarded as suitable prognostic and predictive factors in breast cancer.

Citing Articles

Three-dimensional turbo-spin-echo amide proton transfer-weighted and intravoxel incoherent motion imaging mri for triple-negative breast cancer: a comparison with molecular subtypes and histological grades.

Zhang N, Shao X, Xu L, Zhu W, Wang H, Luo R BMC Cancer. 2025; 25(1):465.

PMID: 40082810 PMC: 11907953. DOI: 10.1186/s12885-025-13879-6.


Breast cancer preclinical models: a vital resource for comprehending disease mechanisms and therapeutic development.

Kaur R, Sharma A, Wijekoon N EXCLI J. 2025; 24:267-285.

PMID: 40071025 PMC: 11895054. DOI: 10.17179/excli2024-7973.


Role of GPX3+ astrocytes in breast cancer brain metastasis activated by circulating tumor cell exosomes.

Huang G, Xu G, Cao Q, Li S, Li H, Zhang X NPJ Precis Oncol. 2025; 9(1):64.

PMID: 40055530 PMC: 11889224. DOI: 10.1038/s41698-025-00833-9.


Replication factor C4, which is regulated by insulin-like growth factor 2 mRNA binding protein 2, enhances the radioresistance of breast cancer by promoting the stemness of tumor cells.

Zhu X, Li P, Qu H, Ai X, Zhao Z, He J Hum Cell. 2025; 38(3):65.

PMID: 40053279 DOI: 10.1007/s13577-025-01197-9.


Profile and clinical significance of SPARCL1 and its prognostic significance in breast cancer.

Xu X, Han Y, Song Y, Zhou Z, Chen S, Liu Y Oncol Lett. 2025; 29(4):196.

PMID: 40046638 PMC: 11880884. DOI: 10.3892/ol.2025.14942.